• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用不同分子特征鉴定技术对同一分子亚型的三阴性乳腺癌细胞系进行分类:对转化研究的启示。

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.

机构信息

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

Insight Genetics Incorporated, Nashville, Tennessee, United Sates of America.

出版信息

PLoS One. 2020 Apr 30;15(4):e0231953. doi: 10.1371/journal.pone.0231953. eCollection 2020.

DOI:10.1371/journal.pone.0231953
PMID:32353087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7192374/
Abstract

The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM) classifies TNBC into five subtypes and a modifier based on immunological (IM) signatures. The molecular signature may differ between cancer cells in vitro and their respective tumor xenografts. We identified cell lines with concordant molecular subtypes regardless of classification algorithm or analysis of cells in vitro or in vivo, to establish a panel of clinically relevant molecularly stable TNBC models for translational research. Gene expression data were used to classify TNBC cell lines using the original and the revised algorithms. Tumor xenografts were established from 17 cell lines and subjected to gene expression profiling with the original 2188-gene algorithm TNBCtype and the revised 101-gene algorithm TNBCtype-IM. A total of six cell lines (SUM149PT (BL2), HCC1806 (BL2), SUM149PT (BL2), BT549 (M), MDA-MB-453 (LAR), and HCC2157 (BL1)) maintained their subtype classification between in vitro and tumor xenograft analyses across both algorithms. For TNBC molecular classification-guided translational research, we recommend using these TNBC cell lines with stable molecular subtypes.

摘要

最近,对将三阴性乳腺癌(TNBC)分为六类的原始算法进行了修订。修订后的算法(TNBCtype-IM)根据免疫(IM)特征将 TNBC 分为五类和一个修饰符。体外癌细胞与其各自的肿瘤异种移植物之间的分子特征可能不同。我们确定了具有一致分子亚型的细胞系,而不管分类算法或体外或体内细胞的分析如何,以建立一组具有临床相关性的分子稳定的 TNBC 模型,用于转化研究。使用原始和修订算法对 TNBC 细胞系进行基因表达数据分类。从 17 个细胞系中建立肿瘤异种移植物,并使用原始的 2188 基因算法 TNBCtype 和修订的 101 基因算法 TNBCtype-IM 进行基因表达谱分析。共有 6 个细胞系(SUM149PT(BL2)、HCC1806(BL2)、SUM149PT(BL2)、BT549(M)、MDA-MB-453(LAR)和 HCC2157(BL1))在两种算法的体外和肿瘤异种移植物分析之间保持了其亚型分类的一致性。对于 TNBC 分子分类指导的转化研究,我们建议使用这些具有稳定分子亚型的 TNBC 细胞系。

相似文献

1
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.运用不同分子特征鉴定技术对同一分子亚型的三阴性乳腺癌细胞系进行分类:对转化研究的启示。
PLoS One. 2020 Apr 30;15(4):e0231953. doi: 10.1371/journal.pone.0231953. eCollection 2020.
2
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.基于最小基因集生成算法以对三阴性乳腺癌患者进行临床亚型分类。
BMC Cancer. 2016 Feb 23;16:143. doi: 10.1186/s12885-016-2198-0.
3
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.三阴性乳腺癌分子亚型的细化:对新辅助化疗选择的影响
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
4
A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.非亚洲女性与台湾女性三阴乳腺癌分子亚型的比较。
Breast Cancer Res Treat. 2017 Jun;163(2):241-254. doi: 10.1007/s10549-017-4195-7. Epub 2017 Mar 15.
5
Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.从基因表达谱中鉴定预测三阴性乳腺癌亚群所需的最小基因数。
Hum Genomics. 2022 Dec 20;16(1):70. doi: 10.1186/s40246-022-00436-6.
6
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.运用整合多组学分析方法揭示三阴性乳腺癌分子异质性
Ann Oncol. 2018 Apr 1;29(4):895-902. doi: 10.1093/annonc/mdy024.
7
Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.三阴性乳腺癌患者不同分子亚型的免疫细胞浸润率。
PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.
8
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.根据 Lehmann 改良分类,接受新辅助卡铂和多西他赛治疗的三阴性乳腺癌队列的病理反应。
Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.
9
Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.雄激素受体在两种三阴性乳腺癌患者来源异种移植模型中的功能特征。
J Steroid Biochem Mol Biol. 2021 Feb;206:105791. doi: 10.1016/j.jsbmb.2020.105791. Epub 2020 Nov 30.
10
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.新辅助化疗后病理完全缓解患者三阴性乳腺癌分子亚型的变化。
JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368.

引用本文的文献

1
Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.靶向纤连蛋白的额外结构域A以改善三阴性乳腺癌的无创检测
J Nucl Med. 2025 Jun 2;66(6):880-885. doi: 10.2967/jnumed.124.268859.
2
Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites.乳腺癌细胞系的代谢谱分析:独特和共享的代谢物
Int J Mol Sci. 2025 Jan 24;26(3):969. doi: 10.3390/ijms26030969.
3
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.用戈沙妥珠单抗靶向难治性三阴性乳腺癌:精准医学的新时代。
Cells. 2024 Dec 22;13(24):2126. doi: 10.3390/cells13242126.
4
A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.一种靶向 CD276/B7-H3 的双载药抗体药物偶联物在三阴性乳腺癌中引发细胞毒性和免疫激活。
Cancer Res. 2024 Nov 15;84(22):3848-3863. doi: 10.1158/0008-5472.CAN-23-4099.
5
Pronecroptotic Therapy Using Ceramide Nanoliposomes Is Effective for Triple-Negative Breast Cancer Cells.使用神经酰胺纳米脂质体的促坏死疗法对三阴性乳腺癌细胞有效。
Cells. 2024 Feb 26;13(5):405. doi: 10.3390/cells13050405.
6
Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer.基底样 2 型三阴性乳腺癌中酪氨酸激酶的预后标志物。
Int J Mol Sci. 2024 Jan 24;25(3):1405. doi: 10.3390/ijms25031405.
7
Multimodal imaging of metabolic activities for distinguishing subtypes of breast cancer.用于区分乳腺癌亚型的代谢活动多模态成像
Biomed Opt Express. 2023 Oct 13;14(11):5764-5780. doi: 10.1364/BOE.500252. eCollection 2023 Nov 1.
8
PML modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer.PML 通过调节染色质的表观遗传组成来调节三阴性乳腺癌中促转移基因的表达。
Nucleic Acids Res. 2023 Nov 10;51(20):11024-11039. doi: 10.1093/nar/gkad819.
9
Recent advances in lab-on-a-chip systems for breast cancer metastasis research.用于乳腺癌转移研究的芯片实验室系统的最新进展。
Nanoscale Adv. 2023 Mar 27;5(9):2375-2393. doi: 10.1039/d2na00823h. eCollection 2023 May 2.
10
Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.作为三阴性乳腺癌生物标志物的亚型特异性酪氨酸激酶的转录组学分析
Cancers (Basel). 2023 Jan 7;15(2):403. doi: 10.3390/cancers15020403.

本文引用的文献

1
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.帕博利珠单抗在一名无肿瘤程序性死亡配体1表达的转移性三阴性乳腺癌患者中的临床活性:病例报告及相关生物标志物分析
JCO Precis Oncol. 2017 Nov;1:1-6. doi: 10.1200/PO.17.00032.
2
Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.通过临床免疫组织化学标志物对乳腺癌细胞系进行分子特征分析。
Oncol Lett. 2017 Jun;13(6):4708-4712. doi: 10.3892/ol.2017.6093. Epub 2017 Apr 25.
3
Molecular characterization of breast cancer cell lines through multiple omic approaches.通过多种组学方法对乳腺癌细胞系进行分子特征分析。
Breast Cancer Res. 2017 Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0.
4
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.三阴性乳腺癌分子亚型的细化:对新辅助化疗选择的影响
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
5
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.基于最小基因集生成算法以对三阴性乳腺癌患者进行临床亚型分类。
BMC Cancer. 2016 Feb 23;16:143. doi: 10.1186/s12885-016-2198-0.
6
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.7 种三阴性乳腺癌分子亚型对新辅助化疗的差异性反应。
Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799. Epub 2013 Aug 15.
7
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.TopHat2:在存在插入、缺失和基因融合的情况下对转录组进行精确比对。
Genome Biol. 2013 Apr 25;14(4):R36. doi: 10.1186/gb-2013-14-4-r36.
8
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.鉴定人类三阴性乳腺癌亚型和临床前模型以选择靶向治疗药物。
J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
9
The Sequence Alignment/Map format and SAMtools.序列比对/映射格式和 SAMtools。
Bioinformatics. 2009 Aug 15;25(16):2078-9. doi: 10.1093/bioinformatics/btp352. Epub 2009 Jun 8.
10
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.用于研究功能不同癌症亚型的乳腺癌细胞系集合。
Cancer Cell. 2006 Dec;10(6):515-27. doi: 10.1016/j.ccr.2006.10.008.